Movetis of Belgium has launched its lead product Resolor in Germany as a treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.

The drug was approved in October, and chief executive Dirk Reyn said that the launch of Resolor (prucalopride) in Germany “is yet another important milestone in the relatively short history of Movetis”. He added that “every day we receive more and more questions from physicians, illustrating there is a clear interest for a product such as Resolor”.

The product meets the criteria for reimbursement in Germany, the company said, and set up its own commercial organisation in that country. It has also entered into an alliance with Quintiles to support Resolor in Germany “and later in other selected European countries”.

Movetis added that it has also set up a collaboration with the UK’s IDIS to provide pre-launch access to Resolor in those countries where the product already has received marketing approval “but where the pricing and reimbursement procedures are still running, and where this is allowed by national regulations”. After Germany, the company is preparing to launch Resolor in the UK in the second quarter of 2010 and says that “pricing and reimbursement procedures are progressing as scheduled”.

Movetis added that the price in the UK will be similar to Germany where the once-daily pill is available in 1mg and 2mg 28-tablet packs. The 1mg pack costs 61.65 euros and 89.68 euros for the 2mg pack.
These are interesting times for Movetis, which was founded in November 2006 as a spin-off of Johnson & Johnson. In December, its initial public offering raised in the region of 100 million euros and the firm says it has a broad portfolio of gastrointestinal products, with two compounds in Phase II development.